High-Dose Naxitamab (Humanized-3F8) Plus Stepped-up Dosing of Granulocyte-Macrophage Colony-Stimulating Factor for Consolidating ≥ 2nd Complete Remission of High-Risk Neuroblastoma

被引：0
|
作者：
Kushner, B. [1 ]
Modak, S. [1 ]
Basu, E. [1 ]
Roberts, S. [1 ]
Mauguen, A. [1 ]
Cheung, N. K. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Pediat, 1275 York Ave, New York, NY 10021 USA
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V349 SIOP1
引用
收藏
页码：S333 / S333
页数：1
相关论文
共 40 条
  • [1] High-Dose Naxitamab (Humanized-3F8) Plus Stepped-up Dosing of Granulocyte-Macrophage Colony-Stimulating Factor for Relapsed Neuroblastoma Resistant to Salvage Therapy: A Phase II Trial
    Kushner, B.
    Modak, S.
    Basu, E.
    Roberts, S.
    Mauguen, A.
    Pandit-Taskar, N.
    Cheung, N. K.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S332 - S332
  • [2] High-Dose Naxitamab (Humanized-3F8) PLUS Stepped-up Dosing of Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma: Outpatient Treament Low Immunogenicity, and Major Responses in a Phase II Trial
    Kushner, B.
    Modak, S.
    Basu, E.
    Roberts, S.
    Mauguen, A.
    Pandit-Taskar, N.
    Cheung, N. K.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S331 - S332
  • [3] High-Dose Naxitamab (Humanized-3F8) Plus Stepped-Up Dosing of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Resistant Osteomedullary Neuroblastoma: Major Responses and Outpatient Treatment in a Phase II Trial
    Kushner, B.
    Modak, S.
    Basu, E.
    Roberts, S.
    Mauguen, A.
    Pandit-Taskar, N.
    Cheung, N-K
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S32 - S32
  • [4] High-Dose Naxitamab Plus Stepped-up Dosing of Granulocyte-Macrophage Colony-Stimulating Factor for High-Risk Neuroblastoma: Efficacy Against Histologically-Evident Primary Refractory Metastases in Bone Marrow
    Kushner, B.
    Modak, S.
    Basu, E.
    Roberts, S.
    Cheung, N. K.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S331 - S331
  • [5] Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission
    Mora, Jaume
    Castaneda, Alicia
    Gorostegui, Maite
    Santa-Maria, Vicente
    Garraus, Moira
    Munoz, Juan Pablo
    Varo, Amalia
    Perez-Jaume, Sara
    Mane, Salvador
    PEDIATRIC BLOOD & CANCER, 2021, 68 (10)
  • [6] Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report
    Mora, Jaume
    Castaneda, Alicia
    Gorostegui, Maite
    Varo, Amalia
    Perez-Jaume, Sara
    Simao, Margarida
    Munoz, Juan Pablo
    Garraus, Moira
    Larrosa, Cristina
    Salvador, Noelia
    Lavarino, Cinzia
    Krauel, Lucas
    Mane, Salvador
    CANCERS, 2023, 15 (09)
  • [7] Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Nysom, Karsten
    Bear, Melissa K.
    Tornoe, Karen
    Kushner, Brian H.
    CANCER REPORTS, 2023, 6 (01)
  • [8] Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma A Phase 1 Clinical Trial
    Kushner, Brian H.
    Cheung, Irene Y.
    Modak, Shakeel
    Basu, Ellen M.
    Roberts, Stephen S.
    Cheung, Nai-Kong
    JAMA ONCOLOGY, 2018, 4 (12) : 1729 - 1735
  • [9] High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): Efficacy against histologically-evident primary refractory metastases in bone marrow (BM).
    Kushner, Brian H.
    Modak, Shakeel
    Basu, Ellen M.
    Roberts, Stephen S.
    Cheung, Nai-Kong V.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission
    Cheung, Nai-Kong V.
    Cheung, Irene Y.
    Kushner, Brian H.
    Ostrovnaya, Irina
    Chamberlain, Elizabeth
    Kramer, Kim
    Modak, Shakeel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) : 3264 - 3270
1234